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Abstract
Background: Incomplete ascertainment of outcomes in randomized controlled trials (RCTs) is
likely to bias final study results if reasons for unavailability of patient data are associated with the
outcome of interest. The primary objective of this study is to assess the potential impact of loss to
follow-up on the estimates of treatment effect. The secondary objectives are to describe, for
published RCTs, (1) the reporting of loss to follow-up information, (2) the analytic methods used
for handling loss to follow-up information, and (3) the extent of reported loss to follow-up.
Methods: We will conduct a systematic review of reports of RCTs recently published in five top
general medical journals. Eligible RCTs will demonstrate statistically significant effect estimates with
respect to primary outcomes that are patient-important and expressed as binary data. Teams of 2
reviewers will independently determine eligibility and extract relevant information from each
eligible trial using standardized, pre-piloted forms. To assess the potential impact of loss to followPage 1 of 11
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Trials 2009, 10:40

http://www.trialsjournal.com/content/10/1/40

up on the estimates of treatment effect we will, for varying assumptions about the outcomes of
participants lost to follow-up (LTFU), calculate (1) the percentage of RCTs that lose statistical
significance and (2) the mean change in effect estimate across RCTs. The different assumptions we
will test are the following: (1) none of the LTFU participants had the event; (2) all LTFU participants
had the event; (3) all LTFU participants in the treatment group had the event; none of those in the
control group had it (worst case scenario); (4) the event incidence among LTFU participants
(relative to observed participants) increased, with a higher relative increase in the intervention
group; and (5) the event incidence among LTFU participants (relative to observed participants)
increased in the intervention group and decreased in the control group.
Discussion: We aim to make our objectives and methods transparent. The results of this study
may have important implications for both clinical trialists and users of the medical literature.

Background
In this paper, we define loss to follow-up as incomplete
ascertainment of the primary outcome for participants
randomized in the trial. If the authors exclude participants
from the analysis, but still provide their primary outcome
data (thus allowing others to conduct an analysis consistent with the intention-to-treat principle), we will consider
that loss to follow-up did not occur. However, if the
authors do not provide the primary outcome data of those
excluded participants, we will consider that loss to followup did occur.
In randomized controlled trials (RCTs) assessing health
care interventions, adherence to key methodological principles helps ensure the validity of the results. The intent of
randomization is to ensure that the treatment and control
groups are similar at baseline with respect to both known
and unknown prognostic factors and confounders. Blinding the trial participants and study personnel to treatment
allocation is intended to ensure that the care provided
(aside from the experimental intervention) and the methods for outcome assessment are similar in between
groups. Ensuring that all randomized patients are analyzed according to the group to which they were randomized preserves the prognostic balance created by
randomization and maintained by blinding.
Incomplete ascertainment of patient outcomes for the
final analysis due to loss to follow-up may bias the results
if the reasons for unavailability of participant data are
associated with the outcome of interest. Attributing outcomes to patients according to the groups to which they
were randomized cannot protect from bias if one doesn't
know what those outcomes were [1]. Investigators can
reduce the amount of missing data, but in most instances
cannot eliminate it [2]. How to best deal with missing
data remains controversial; one interpretation of the
"intention to treat principle" is that it requires imputing
the missing data [3]. The Consolidated Standards of
Reporting Trials (CONSORT) flow diagram is intended to
render explicit the information necessary to make a judg-

ment about loss to follow-up and attribution of events to
patients according to randomization (or otherwise) [4,5].
The extent of loss to follow-up in RCTs and the investigators' approach to dealing with the problem has been the
subject of a number of studies. Hollis et al. surveyed all
RCTs published in 1997 in 4 "top" medical journals (n =
249) and found that 75% of the trials had missing data for
the primary outcome. The most frequently used strategy
(45%) for handling missing data was to restrict analysis to
those with full outcome information (complete case analysis) [6].
Wood et al. examined all RCTs published over 6 months
in 2001 in 4 "top" medical journals (n = 71) and found
that 89% of trials had missing outcome data, 65% of
which used complete case analysis in their primary analysis [7]. In a more recent study of RCTs reported in 10 medical journals in 2002, Gravel et al. found that more than
60% of articles claiming the use of an intention-to-treat
approach (n = 249) had missing data in their primary
analysis with few articles reporting a specific strategy for
dealing with missing data [8].
Baron et al. examined the rate of missing data in superiority trials published between 1994 and 2003 that assessed
structural outcomes in rheumatic diseases (n = 81) [9].
They were able to determine the rate of missing data in
78% of reports; in approximately one-third of these
reports the rate was >20%. Only 24% reported statistical
methods for handling missing data. Although missing
data is not as problematic in interpreting the results of an
individual trial with statistically non-significant effect estimates, none of the three aforementioned studies distinguished between negative and positive studies when
reporting about handling missing data.
Several studies have evaluated the association between the
extent of reported loss to follow-up and the magnitude of
treatment effects. Among 190 primary RCTs from 14
meta-analyses (search year 2000), Kjaergard et al. found
Page 2 of 11
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that reported follow-up was not significantly associated
with estimated intervention effects [10]. In a study of 276
RCTs from 26 meta-analyses (search year 2000), Balk et al.
found that recording of patients lost to follow-up (LTFU),
the reason for dropouts, and percentage of enrolled
patients who dropped out, were not statistically significantly associated with treatment effect [11]. In a 1995
study of 250 controlled trials from 33 meta-analyses,
Schulz et al. found that excluding participants after randomization was not significantly associated with the magnitude of effect [12]. Tierney et al. analyzed 14 metaanalyses of individual patient data to investigate whether
patients' exclusion from analysis affected the results of trials and meta-analyses [13]. Considering individual trials,
they did not find evidence that exclusion of patients
altered their results. However, meta-analyses based only
on 'included' patients tended to favor the intervention
under investigation.
Thus, in spite of the theoretical concerns, no study has
found evidence of a statistically significant association
between loss to follow-up and the magnitude of treatment
effect. There are a number of possible explanations for this
apparent lack of association. The first possibility is that
loss to follow-up does not bias trial results. However, this
explanation is unlikely in the light of evidence that
patients LTFU often have worse outcomes than those who
are not LTFU [14,15]. The second possibility is that the
association between loss to follow-up and treatment effect
is confounded by the adequacy of reporting loss to followup. Schulz et al showed that trials reporting exclusions
were generally of a higher methodological quality than
those that did not. This suggests that exclusions may have
been present but not reported in some trials of lower
methodological quality [16]. A third possibility is that
loss to follow-up does bias the treatment effect but the
rates of loss to follow-up are low enough that the above
mentioned studies lacked power to detect any association.
A final possibility is that loss to follow-up leads to bias
that varies in direction both between trials leading to an
overall lack of association when considering a number of
trials together.
The primary objective of this study is to assess the potential impact of loss to follow-up on the estimates of treatment effect. The secondary objectives are to describe, for
published RCTs, (1) the reporting of loss to follow-up
information, (2) the analytic methods used for handling
loss to follow-up information, and (3) the extent of
reported loss to follow-up.

http://www.trialsjournal.com/content/10/1/40

cally significant effect estimates with respect to primary
outcomes that are patient-important and expressed as
binary data.
As mentioned earlier, we define loss to follow-up as
incomplete ascertainment of the primary outcome for
subjects randomized in the trial. If the authors exclude
participants from the analysis, but still provide their primary outcome data (thus allowing others to conduct an
analysis consistent with the intention-to-treat principle),
we will consider that loss to follow-up did not occur.
However, if the authors do not provide the primary outcome data of those excluded participants, we will consider
that loss to follow-up did occur.
Eligibility criteria
The inclusion criteria are:

1. Study published in the five general medical journals
ranked the highest according to the number of citations
reported in the Journal Citation Report (JCR) by Thomson
ISI (Institute for Scientific Information) in 2008: New
England Journal of Medicine (NEJM), Lancet, Journal of
the American Medical Association (JAMA), British Medical Journal (BMJ), and Annals of Internal Medicine.
2. Study is described by its authors as a RCT;
3. Primary outcome is a patient-important outcome
(defined below);
4. Binary data, allowing the construction of a 2 × 2 table,
are reported for the primary outcome. This includes
binary summaries of continuous outcomes (e.g. pain
reduction of 50% or more), or of time to event outcomes
(e.g. proportion surviving to 2 years). Trials with time to
event outcomes qualify only if data for 2 × 2 tables are
available and an effect estimate (i.e. relative risk) calculated from the 2 × 2 table remains statistically significant.
We acknowledge that the proportion we are calculating
for time to event data (number of subjects with events
divided by number randomized) as well as the upper and
lower values of its confidence interval are not exactly risks
and plan a sensitivity analysis excluding these trials.
The exclusion criteria are:
1. Study described as RCT but is not truly randomized. We
will use Cochrane criteria for judging risk of bias [17] as
related to sequence generation to judge whether a study is
truly a RCT;

Methods
Overall study design
We will conduct a systematic review of reports of RCTs
recently published in five general medical journals with
the highest citation rates. Eligible trials will report statisti-

2. Cluster RCT;
3. Cross-over RCT;
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4. n-of-1 RCT;
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6. Meta-analysis of 2 or more previously published RCTs;

cardiovascular outcomes [19] and was developed through
consensus discussions of the relative importance of outcomes identified from RCTs eligible for inclusion in the
current study. Categories I, II, and III but not category IV
include patient-important outcomes.

7. Primary outcome is not statistically significant. (See
Appendix 1 for LOST-IT rules for judging statistical significance);

Categories of loss to follow-up
We will use the following mutually exclusive categories of
subjects to classify reasons for potential loss to follow-up:

8. Primary outcome is a composite endpoint with at least
one component not patient-important;

1. Mistakenly randomized with inappropriate post-randomization exclusion;

9. Primary outcome based on registries (e.g. death registry), if the authors do not report any other eligible outcome;

2. Not received intervention with inappropriate post-randomization exclusion;

5. RCT reported in a research letter

3. Withdrew consent;
10. Primary outcome is binary but is reported only as a
rate (e.g. 100 death/10,000 person years).
The unit of analysis for the LOST-IT study will be a report
of an RCT, not the RCT itself. Consequently, we may
include more than one report of the same RCT as long as
each meets the eligibility criteria. For example, we will
include, if otherwise eligible, reports of secondary analyses, reports of subgroup analyses, and reports of longer
follow-up of RCTs, even if the allocation code was broken.
The rationale for the decision to include reports of secondary and sub-group analyses is that, conceptually, we
are interested in the extent to which any reports of RCTs
in a set of prestigious journals may be misleading as a
result of LFUP.
For multiple-arm RCTs and RCTs with a factorial design,
we will only consider a comparison with statistically significant results. If there is more than one comparison with
statistically significant results, we will choose the one with
the largest effect estimate expressed in relative terms (e.g.,
relative risk reduction). For RCTs with multiple follow-up
times, we will use the longest follow-up time that is associated with a statistically significant result.
Patient-important outcomes
Patients typically assign varying importance to different
health outcomes [18]. We define a patient-important outcome as an outcome for which one would answer with
"yes" the following question: "if the patient knew that this
outcome was the only thing to change with treatment,
would patient consider receiving this treatment if associated with side effects or cost?" To focus our study on
patient-important outcomes and to explore our findings
across different levels of patient importance, we developed a hierarchy of outcomes (Appendix 2). This hierarchy is adapted from that used in another study of

4. Non-adherent;
5. Crossed-over;
6. Lost contact.
Mistakenly randomized subjects are those that were ineligible at the time of randomization. We will consider postrandomization exclusion inappropriate if either: (1) the
information about ineligibility was not available at randomization; or (2) the individual making the exclusion
decision was not blinded to allocation. For participants
who did not receive the intervention we will consider
their post-randomization exclusion inappropriate if
patients were not blinded to their allocation. For survival
data, we will not consider as LTFU those subjects that are
censored because of the planned termination of study. We
will consider all post randomization exclusions related to
study center exclusion as appropriate. Figure 1 shows
these different categories within the LOST-IT framework
illustrating issues related to loss to follow-up and threats
to validity for binary outcomes.
Literature search
We will electronically search Medline (OVID interface)
using the Cochrane Collaboration's "highly sensitive"
search strategy to identify reports of RCTs in Medline
(Additional file 1). The search will be restricted to human
studies.
Review process
Reviewers trained in health research methodology will
work in pairs. They will perform each of the review stages
(selection of studies, selection of the primary outcome,
and data abstraction) in duplicate and independently.
They will attempt to resolve any disagreements by discussion and, when unsuccessful, with the assistance of an
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Figure
LOST-IT1framework illustrating issues related to loss-to-follow-up and threats to validity for binary outcomes
LOST-IT framework illustrating issues related to loss-to-follow-up and threats to validity for binary outcomes.

arbitrator. One person (EAA) will serve as the arbitrator
for all studies. For resolving disagreements related to data
abstraction, the arbitrator will independently abstract
data prior to discussions with the 2 reviewers. Before starting data abstraction, we will conduct calibration exercises
to ensure consistency between reviewers, through sampling papers from the 5 journals under review.
We will use paper forms for title and abstract screening
and electronic forms, hosted by a university central server,
for full text screening and data abstraction. The full text
articles of potentially eligible RCTs (and supporting documentation) will also be available electronically on the
central server.
Selection of studies
Teams of 2 reviewers will screen the titles and abstracts of
identified citations for potential eligibility using a standardized, pilot-tested, title and abstract screening form
with corresponding detailed written instructions (Additional file 2). They will document the screening outcome
and reason for exclusion (if applicable). The reviewers will
then screen the full texts of potentially eligible RCTs for
eligibility. They will use a standardized, pilot-tested full
text screening form with corresponding detailed written
instructions.

Selection of the primary outcome
Before extracting data from an eligible RCT, teams of 2
reviewers will select the primary outcome as follows. If the
report specifies a single primary outcome, we will select it
as the primary outcome for LOST-IT. If the report specifies
primary outcomes for both efficacy and safety, we will
select the primary efficacy outcome. If the report specifies
multiple primary outcomes, we will select the statistically
significant outcome in the highest category on the outcome hierarchy (Appendix 2). If the report does not specify a primary outcome, we will select the outcome with the
highest category on the outcome hierarchy that is statistically significant.
Data abstraction
Reviewer teams will abstract data from eligible RCTs using
a pilot-tested standardized data abstraction form (Additional file 3) with corresponding detailed instructions. We
will also search for and use additional data related to the
RCT of interest reported in ACP Journal Club, errata, or
trial protocols published in peer review journals. For
LTFU information, however, we will use only data from
the report under consideration (e.g. we will not use for a
report of a subgroup analysis a participant flow diagram
from the original report not considering the specific subgroup).
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We will extract information about the study background,
methodological quality, reporting of loss to follow-up,
analytic methods used for handling LTFU information,
and loss to follow-up statistical data regarding the primary
analysis of the primary outcome as selected for LOST-IT
(See Additional file 4 for more details about reporting of
loss to follow-up, analytic methods used for handling loss
to follow-up information, and loss to follow-up statistical
data).
We will determine the follow-up status and analysis of
each category of subjects potentially lost to follow-up
(Figure 1) as follows: (1) unclear whether followed up,
(2) not followed up, (3) followed-up, not included in the
analysis, (4) analyzed in a group to which they were not
randomized (for crossed over and non-adherent). We will
also determine for each category whether loss to followup was reported to be related to side effects or adverse
events, or other specified reasons.
We will always consider the negative aspect of an outcome
(e.g. mortality instead of survival). We will define participants' non-adherence to the intervention according to the
author's definition. When there is no explicit statement
(or flow diagram) indicating that no participants were
LTFU, we will assume that this was actually the case if the
following 3 conditions are met:
i. all protocol deviations were explicitly described and
detailed;
ii. the authors explicitly stated that all enrolled participants were included in the analyses
iii. the outcome is mortality, as it is less likely that the
investigators would have LTFU for that outcome.
We will contact the authors and send them the results of
our data abstraction to give them the opportunity to confirm them or refute them.
Sample size
We estimate that we will identify about 200 eligible
papers by applying our search strategy to the years 2005–
2007. A sample size of 200 would result in the following
confidence intervals for 3 plausible proportions (10%,
20% and 30%) of articles losing statistical significance in
our analysis: (5.84–14.16); (14.46–25.54); and (23.65–
36.35) respectively. We find these confidence intervals to
be acceptable.
Analysis
Agreement
We will assess agreement between reviewers for study
inclusion both at the title and abstract screening and the

http://www.trialsjournal.com/content/10/1/40

full text screening stage. We will calculate both crude
agreement and chance-corrected agreement (kappa statistic). If fewer than 15% or more than 85% of citations are
included in this study, we will measure agreement using
chance-independent agreement (phi statistic). We will
interpret the agreement statistics using the guidelines proposed by Landis and Koch [20]: kappa values of 0 to 0.20
represent slight agreement, 0.21 to 0.40 fair agreement,
0.41 to 0.60 moderate agreement, 0.61 to 0.80 substantial
agreement, and greater than 0.80 almost perfect agreement. We will use these same thresholds for interpreting
phi.
Reporting of loss to follow-up information
We will calculate the following (denominator = number
of RCTs included in the review):

1. the proportion of RCTs that explicitly reported whether
LTFU occurred or not (either in general or specifically
relating to the above defined categories);
2. the proportion of RCTs that reported a CONSORT flow
diagram with LTFU provided;
3. the proportion of RCTs that reported loss to follow-up
separately for the 2 comparison groups;
4. the proportion of RCTs that reported loss to follow-up
at each planned outcome assessment;
5. the proportion of RCTs that compared the baseline
characteristics of participants LTFU to those not LTFU and
the proportion that compared the baseline characteristics
of those LTFU in intervention and control groups;
6. the proportion of trials that discussed the implications
of loss to follow-up in the context of their findings
Analytic methods used for handling LTFU information
We will calculate the proportion of RCTs that reported the
analytic methods used for handling LTFU information.
We will also calculate among RCTs reporting loss to follow-up information:

1. the percentage of RCTs, using the term "intention to
treat" and "modified intention to treat";
2. the percentages of RCTs with different types of post randomization exclusions (i.e. mistakenly randomized, no
intervention received and center exclusion) that are
respectively appropriate and inappropriate;
3. the percentage of RCTs in which participants for whom
outcome data is available were analyzed in the group to
which they were randomized.
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4. The analytical method used for dealing with LTFU
information in the primary analysis and any additional
analyses of the primary outcome.
Extent of reported loss to follow-up
For each trial, we will calculate (for each group and for the
entire cohort) the percentage of total participants classified as LTFU according to our study definition. We will
then calculate the mean and standard deviation of the percentage across trials. We will repeat the calculations for
the following 3 categories:

• Not followed up: mistakenly randomized and inappropriately excluded; not received intervention and inappropriately excluded; withdrew consent and not followed up;
cross over and not followed up; non adherent and not followed up; lost contact with participants and no other
source of outcome data;
• Followed up but not included in the analysis: withdrew consent, followed up but not included in the analysis; cross
over, followed up but not included in the analysis; nonadherent, followed up but not included in the analysis;
• Unclear whether followed up: withdrew consent and
unclear whether followed up; cross over and unclear
whether followed up; non adherent and unclear whether
followed up;
• Analyzed in a group to which they were not randomized:
cross over, followed up but analyzed in a group to which
they were not randomized; non-adherent, followed up
but analyzed in a group to which they were not randomized.
For each trial, we will also calculate for each group and for
the entire trial the "LTFU to events ratio" (i.e. the ratio of
the total number of participants classified as LTFU,
according to this study definition, to the number of primary outcome events). We will then calculate the mean
and standard deviation of the ratio across trials.
We will then conduct regression analyses with "percentage
of participants LTFU" as the dependent variable. We will
use two sets of independent variables:
• General trial characteristics: number of study centers,
type of funding, type of outcome (mortality vs. others),
clinical area (medical vs. surgical), type of intervention
(pharmacological vs. surgery/invasive procedure vs.
other), and length of follow-up
• Methodological trial characteristics: concealing allocation,
blinding, stopping early for benefit, reporting the use of
"ITT" analysis, and analyzing participants as randomized.

http://www.trialsjournal.com/content/10/1/40

We will re-categorize the variables funding, intervention,
and blinding and consider them for the regression model
on the basis of their empirical distribution. We will use
weighted linear regression models, with the weight for
each observation being defined as the inverse of the estimated variance of the observed outcome (dependent) variable. This weighting has the effect of giving more
emphasis to observations that are relatively precise (and
subject to less sampling variation), and corresponding
less emphasis to observations with greater sampling variation. It also has the advantage of satisfying the regression
assumption of homogeneity in the (weighted) residuals.
We will include only studies reporting LTFU information.
Potential impact of loss to follow-up
We will conduct analyses to test the effect of different
assumptions about the outcomes of participants LTFU on
the effect estimate for the primary outcome. We will use
data from the 2 × 2 tables for all these analyses. For papers
reporting a survival analysis we will include the LTFU participants in the denominator. For each of the assumptions, we will calculate (1) the percentage of RCTs that
lose statistical significance; and (2) the mean change in
effect estimate across RCTs. We will compare the relative
risk (RR) for each assumption with the RR based on the 2
following "base cases":

1. A complete case analysis excluding LTFU participants
from both the denominator and numerator;
2. The approach to generating effect estimate reported by
the investigators.
While including LTFU participants in the denominator we
will test the following assumptions about the events
among participants LTFU:
1. None of the LTFU participants had the event;
2. All LTFU participants had the event;
3. All LTFU participants in the treatment group had the
event; none of those in the control group had it (worst
case scenario);
4. LTFU participants had higher event incidences than the
observed participants in their respective randomization
groups, but the relative increase was higher for the intervention group (e.g. 30% for the intervention group, 10%
for the control group). We define RILTFU/FU as the relative
increase in event rate of those LTFU compared to those
followed up. We will pre-specify a number of combinations of RILTFU/FU for the intervention and control groups.
The maximum possible value of RILTFU/FU for a specific
event rate corresponds to an increase of that event rate to
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100%. Tables 1 and 2 in Additional file 5 represent the
dummy tables for these analyses and the values of RILTFU/
FU are just illustrative. We continue to explore the literature for evidence to support our choices;
5. LTFU participants in the intervention group had a
higher event incidence than their randomization group,
and LTFU participants in the control group had a lower
event incidence than their randomization group. We
define RDLTFU/FU as the relative decrease in event rate of
those LTFU compared to those followed up. We will prespecify a number of combinations of RILTFU/FU for the
intervention and RDLTFU/FU for the control group. Tables 3
and 4 in Additional file 5 represent the dummy tables for
these analyses.
We will then conduct regression analyses with "delta log
of effect estimate" as the dependent variable. We will use
two sets of independent variables:
• General trial characteristics: number of study centers,
type of funding, type of outcome (mortality vs. others),
clinical area (medical vs. surgical), type of intervention
(pharmacological vs. surgery/invasive procedure vs.
other), and length of follow-up
• Methodological trial characteristics: concealing allocation, blinding, stopping early for benefit, reporting the use
of "ITT" analysis, and analyzing participants as randomized.
We will re-categorize the variables funding, intervention,
and blinding and consider them for the regression model
on the basis of their empirical distribution. We will use
weighted linear regression models, with the weight for
each observation being defined as the inverse of the estimated variance of the observed outcome (dependent) variable.
The primary analyses will include all studies while the
sensitivity analyses will exclude studies reporting time-toevent data

Discussion
This protocol describes a methodological study the goal of
which is to assess the potential impact of loss to follow-up
information in published RCTs on the estimates of treatment effect. By publishing our detailed study protocol we
make our objectives and methods transparent [21].
Strengths of our study include its transparent and systematic methods with respect to searching for eligible reports,
selecting eligible studies, selecting the primary outcomes
and abstracting data. We will ensure data integrity by preparing detailed written instructions, conducting formal

http://www.trialsjournal.com/content/10/1/40

calibration exercises, and measuring agreement between
pairs of reviewers.
We will focus on reports of trials with statistically significant effect estimates published in major general medical
journals because these studies are more likely to influence
clinical practice than studies with non-significant effect
estimates or studies published in lower profile journals. In
addition missing data is not as problematic in interpreting
the results of an individual trial with non-statistically significant effect estimates. This decision is likely to affect the
representativeness of the reports we are including and our
ability to completely uncover the potential problems.
There is indirect evidence that RCTs published in top
medical journals tend to report larger effect estimates than
those published in lower profile journals [22]. In addition, RCTs published in top medical journals are typically
of higher methodological quality [23] and thus likely to
suffer from lower rates of loss to follow-up. Given that the
trial reports we are focusing on report larger effect estimates and lower rates of loss to follow-up, our findings
will likely represent a "best case" scenario of the potential
impact of loss to follow-up information on the estimates
of treatment effect in published RCTs.
The type of outcome and the timing of its assessment are
likely to be associated with the extent of loss to follow-up.
Loss to follow-up is, for instance, likely to be lower for survival compared to a measurement of quality of life. Similarly, in a trial of an analgesic, loss to follow-up is likely to
be lower for pain at day 2 compared to pain at 1 year. We
are thus categorizing the type of outcome and recording
the timing of its assessment. Our use of a newly developed
outcome hierarchy for selecting and categorizing the primary outcome for each trial may be questionable. We
have, however, used a systematic approach to adapt a previous hierarchy. Our approach in developing this previous
hierarchy, moreover, was accepted by editors and reviewers of a prominent journal and has not, to our knowledge,
elicited adverse criticism. We will use this hierarchy only
for reports not specifying the primary outcome of the trial
– the number of which should be relatively small. Finally,
we are selecting the primary outcome in duplicate and
independent fashion which will allow us to establish the
reproducibility of the judgment.
We have specifically chosen not to include RCTs reporting
primary outcomes that are continuous variables or
expressed as rates, because of specific challenges related to
analyzing and reporting LTFU information in those trials,
e.g. use of last value carried forward with continuous outcomes [3]. We hope to conduct a separate study for continuous variables. For the same reasons, we did not
include RCTs that have a cluster or cross-over design. Consequently, our results will be pertinent to parallel arm
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RCTs and factorial RCTs reporting results in a binary fashion.

Authors' contributions

To assess the potential impact of loss to follow-up information on effect estimates we will consider a number of
assumptions about the outcomes of participants LTFU.
The first 2 assumptions (none of the LTFU participants
had the event, all LTFU participants had the event) are less
plausible but frequently used and/or discussed in the literature. The 3rd assumption (worst case scenario) is an
extreme and in most cases unrealistic assumption. However, it is valuable in demonstrating the robustness of a
trial results when the effect estimate remains statistically
significant even under the assumption of a worst-case scenario. The remaining 2 assumptions (assuming that LTFU
participants have different event incidences than the
observed group) are more plausible and designed (in
terms of differential extent and direction between intervention and control) to test the robustness of effect estimates. The challenge is to choose plausible values for
RILTFU/FU and RDLTFU/FU. The values we use in our dummy
tables are just illustrative and we are continuing to explore
the literature for evidence to support our choices. For
example, a recent report on antiretroviral therapy scale-up
programs in Africa found that the incidence of death
among participants LTFU was 5 times as high as the incidence in those followed-up [14]. While other imputation
methods such as regression models and multiple imputations might be preferable, they are not feasible because
they would require raw data from each included study.

Appendix 1

All authors contributed the design of this protocol.

LOST-IT rules for judging statistical significance
The rules for judging statistical significance will be the following:

• p-value < 0.05;
• CI not including 1.0 when no p-value is reported;
• Statistical significance is relative to the null hypothesis that difference between groups is 0, irrespective of
whether the study was a superiority, equivalence, or
non-inferiority trial;
• If both intention to treat and per protocol analyses
are reported, we will consider the statistical significance of the former;
• If both unadjusted and adjusted analyses are
reported, we will consider the statistical significance of
the former.

Appendix 2
LOST-IT hierarchy of outcomes relative to patient
importance; examples included in brackets
I. Mortality

1. all cause mortality
The results of this study should have important implications for trialists. Evidence of vulnerability will call for
improving both trial design and implementation, to minimize LTFU. The results of our study will also have important implications for clinicians interpreting the findings of
RCTs. Our findings will uncover the potential impact of
plausible assumptions about the outcome of participants
LTFU on the results of those positive studies that are most
likely to affect clinical practice. They might provide reassurance that these results are usually – at least for reports
in five prestigious journals – robust or, on the contrary,
suggest that many high-profile trials are vulnerable. We
may also find that results vary in robustness and users of
the literature will have to evaluate them on a case by case
basis using clinically plausible assumptions. Our fondest
hope is to help create a culture in which investigators uniformly test alternative assumptions regarding LTFU and
discuss the extent of the vulnerability of their findings to
varying assumptions regarding LTFU.

Competing interests

2. disease specific mortality
II. Morbidity
1. cardiovascular major morbid events
2. other major morbid events (e.g. loss of vision,
seizures, fracture, revascularization)
3. onset/recurrence/relapse/remission of cancer
and other chronic diseases (e.g. COPD exacerbation, new onset of diabetes)
4. renal failure requiring dialysis
5. hospitalization, medical and surgical procedures (e.g. placement of a pacemaker, and cardioversion)
6. infections
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7. dermatological/rheumatologic disorders
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III. Symptoms/Quality of life/Functional status (e.g.
failure to become pregnant, successful nursing/breastfeeding, depression)
Surrogate outcomes (e.g. viral load, physical activity,
weight loss, cognitive function, recurrent polyps, adherence to medication)
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